Findings

What do systematic reviews say?

5 questions · 9 findings · 2 reviews · Infectious Diseases

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 0 · 0%Moderate 2 · 22.2%High 5 · 55.6%

All serious adverse events · children

Rotarix leads to lower all serious adverse events compared with placebo (high certainty).

3 findings from 1 review

Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High

All serious adverse events · children

RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).

3 findings from 1 review

Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate

All serious adverse events · children

Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
3 studies · 11646 participants
High

All serious adverse events · children

Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
RR 0.93 [0.85, 1.02]
3 studies · 8210 participants
Moderate

Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection

The review found no eligible studies for this question.

1 finding from 1 review

Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found